MX9800190A - Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t. - Google Patents

Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t.

Info

Publication number
MX9800190A
MX9800190A MX9800190A MX9800190A MX9800190A MX 9800190 A MX9800190 A MX 9800190A MX 9800190 A MX9800190 A MX 9800190A MX 9800190 A MX9800190 A MX 9800190A MX 9800190 A MX9800190 A MX 9800190A
Authority
MX
Mexico
Prior art keywords
cell mediated
preparations
treatment
mediated diseases
methods
Prior art date
Application number
MX9800190A
Other languages
English (en)
Other versions
MXPA98000190A (es
Inventor
Irun R Cohen
Dana Elias
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MXPA98000190A publication Critical patent/MXPA98000190A/es
Publication of MX9800190A publication Critical patent/MX9800190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

Emulsiones de lipidos metabolizables, tales como Intralipid y LIpofundin, son vehículos excelentes para terapia peptídica de enfermedades autoinmunes y otras enfermedades o condiciones mediadas por células T, TH1, ya que promueve un cambio de citocinas de TH1 o TH2", dichas emulsiones se pueden usar junto con un antígeno reconocido por células T inflamatorias asociadas con la patogénesis de una enfermedad o condicion mediada por células T para el tratamiento terapéutico de dicha condicion.
MX9800190A 1995-07-05 1996-07-02 Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t. MX9800190A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases
IL114458 1995-07-05
PCT/US1996/011373 WO1997002016A1 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases

Publications (2)

Publication Number Publication Date
MXPA98000190A MXPA98000190A (es) 1998-04-01
MX9800190A true MX9800190A (es) 1998-04-30

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800190A MX9800190A (es) 1995-07-05 1996-07-02 Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t.

Country Status (22)

Country Link
EP (1) EP0837672B9 (es)
JP (2) JP4357595B2 (es)
KR (1) KR100435040B1 (es)
CN (1) CN1102382C (es)
AT (1) ATE254451T1 (es)
AU (1) AU714970B2 (es)
CA (1) CA2226013C (es)
CZ (1) CZ298A3 (es)
DE (1) DE69630787T2 (es)
DK (1) DK0837672T3 (es)
ES (1) ES2211963T3 (es)
HR (1) HRP960315A2 (es)
HU (1) HU223081B1 (es)
IL (2) IL114458A0 (es)
MX (1) MX9800190A (es)
NO (1) NO320363B1 (es)
PT (1) PT837672E (es)
SI (1) SI0837672T1 (es)
UY (1) UY24275A1 (es)
WO (1) WO1997002016A1 (es)
YU (1) YU40796A (es)
ZA (1) ZA965666B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
WO2003096967A2 (en) 2002-05-21 2003-11-27 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
WO2005048914A2 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
EP1945246A4 (en) 2005-09-22 2009-03-11 Irun R Cohen IMMUNOGENIC FRAGMENTS OF CONSTANT DOMAINS OF THE T CELL RECEPTOR AND PEPTIDES DERIVED THEREFROM
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
SI0837672T1 (en) 2004-04-30
HU223081B1 (hu) 2004-03-29
PT837672E (pt) 2004-03-31
DE69630787T2 (de) 2004-10-07
UY24275A1 (es) 2000-12-29
CZ298A3 (cs) 1998-06-17
AU6484496A (en) 1997-02-05
JP4357595B2 (ja) 2009-11-04
YU40796A (sh) 1998-11-05
ATE254451T1 (de) 2003-12-15
IL122755A0 (en) 1998-08-16
JP2009242412A (ja) 2009-10-22
DK0837672T3 (da) 2004-03-22
ES2211963T3 (es) 2004-07-16
EP0837672A4 (en) 1999-01-27
NO980013D0 (no) 1998-01-02
CN1102382C (zh) 2003-03-05
DE69630787D1 (de) 2003-12-24
IL122755A (en) 2004-07-25
HRP960315A2 (en) 1998-02-28
JPH11508899A (ja) 1999-08-03
CA2226013C (en) 2012-09-18
HUP9802834A2 (hu) 1999-03-29
EP0837672A1 (en) 1998-04-29
NO320363B1 (no) 2005-11-28
EP0837672B9 (en) 2005-06-15
ZA965666B (en) 1997-01-27
NO980013L (no) 1998-02-19
AU714970B2 (en) 2000-01-13
EP0837672B1 (en) 2003-11-19
CN1193907A (zh) 1998-09-23
WO1997002016A1 (en) 1997-01-23
CA2226013A1 (en) 1997-01-23
HUP9802834A3 (en) 2001-08-28
KR19990028738A (ko) 1999-04-15
KR100435040B1 (ko) 2004-08-18
IL114458A0 (en) 1995-11-27

Similar Documents

Publication Publication Date Title
IL122755A0 (en) Preparations and methods for the treatment of T cell mediated diseases
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
EP0751781A4 (en) METHOD FOR PREVENTING OR TREATING A DISEASE, CHARACTERIZED BY THE NEOPLASTIC CELLS EXPRESSING CD40
AU3844297A (en) Treatment of autoimmune diseases
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT879056E (pt) Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
MXPA03001167A (es) Proteinas y peptidos de tension y metodos para su uso.
Chen What's new about the mechanism of methotrexate action in psoriasis?
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
HUP9901077A2 (hu) Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
Maurer Regulation of the antigen-presentation capacity of human dermal fibroblasts by gamma-interferon.
Ishida et al. Nutritional and immunological assessment in patients with malignant obstructive jaundice--the influence of preoperative biliary decompression and abdominal surgery
EP1052285A3 (en) Method of inducing an antigen-specific anticytotoxic cell
UA28518A (uk) Спосіб визначення алергену у хворих на лікарську хворобу
Wrigley et al. Normal cerebral function with bilateral carotid occlusion
WO2001038394A3 (en) Polypetptides and methods for thymic vaccination
Novales-Li In vitro immunopharmacologic effect of suramin on modifying Th-subset cytokine levels in splenocytes and T-cell clones: a therapeutic application for autoimmune disease
UA6640A (uk) Спосіб прогнозування загострення супутнього захворювання при активізації основної патології
UA34283A (uk) Спосіб діагностики порушень імунологічного статусу у людини та тварин